Jeffrey Kordower to Humans
This is a "connection" page, showing publications Jeffrey Kordower has written about Humans.
Connection Strength
2.703
-
Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
Score: 0.051
-
Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handb Clin Neurol. 2023; 192:57-71.
Score: 0.049
-
In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
Score: 0.046
-
The Unbearable Lightness of Brundin. J Parkinsons Dis. 2022; 12(4):1069-1072.
Score: 0.045
-
GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
Score: 0.043
-
Reply to: "Cell Therapy for Huntington's Disease: Learning from Failure". Mov Disord. 2021 03; 36(3):788-789.
Score: 0.043
-
Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis. 2021 01; 148:105184.
Score: 0.042
-
Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". Mov Disord. 2020 11; 35(11):2120-2121.
Score: 0.042
-
Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in?vivo. Stem Cells Transl Med. 2021 02; 10(2):278-290.
Score: 0.042
-
A Failed Future. Mov Disord. 2020 08; 35(8):1299-1301.
Score: 0.041
-
Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. Mov Disord. 2020 08; 35(8):1312-1314.
Score: 0.041
-
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
Score: 0.040
-
Immunotherapy in Parkinson's disease: Current status and future directions. Neurobiol Dis. 2019 12; 132:104587.
Score: 0.039
-
Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem. 2019 09; 150(5):605-611.
Score: 0.038
-
Temporal evolution of microglia and a-synuclein accumulation following foetal grafting in Parkinson's disease. Brain. 2019 06 01; 142(6):1690-1700.
Score: 0.038
-
Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease. Mov Disord. 2019 09; 34(9):1274-1278.
Score: 0.038
-
Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier? Mov Disord. 2019 09; 34(9):1279-1282.
Score: 0.037
-
Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic Factors. Mov Disord. 2018 05; 33(5):678-683.
Score: 0.035
-
Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018 03; 83(3):562-574.
Score: 0.035
-
Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis. 2018 04; 112:106-118.
Score: 0.034
-
Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
Score: 0.034
-
Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
Score: 0.034
-
Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
Score: 0.033
-
Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In?Vivo. Stem Cell Reports. 2017 07 11; 9(1):149-161.
Score: 0.033
-
Aging and Parkinson's disease: Different sides of the same coin? Mov Disord. 2017 Jul; 32(7):983-990.
Score: 0.033
-
What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. Mov Disord. 2017 04; 32(4):483-484.
Score: 0.033
-
Targeting a-Synuclein as a therapy for Parkinson's disease: The battle begins. Mov Disord. 2017 02; 32(2):203-207.
Score: 0.032
-
Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
Score: 0.032
-
How strong is the evidence that Parkinson's disease is a prion disorder? Curr Opin Neurol. 2016 Aug; 29(4):459-66.
Score: 0.031
-
Fetal grafts for Parkinson's disease: Decades in the making. Proc Natl Acad Sci U S A. 2016 Jun 07; 113(23):6332-4.
Score: 0.031
-
AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
Score: 0.030
-
Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
Score: 0.030
-
Trophic factors for Parkinson's disease: To live or let die. Mov Disord. 2015 Nov; 30(13):1715-24.
Score: 0.030
-
Parkinson's disease and prion disease: Straining the comparison. Mov Disord. 2015 Nov; 30(13):1727.
Score: 0.030
-
The native form of a-Synuclein: Monomer, tetramer, or a combination in equilibrium. Mov Disord. 2015 Dec; 30(14):1870.
Score: 0.029
-
The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep. 2015 May; 15(5):28.
Score: 0.029
-
Gene therapy for Parkinson's disease: still a hot topic? Neuropsychopharmacology. 2015 Jan; 40(1):255-6.
Score: 0.028
-
Special issue on stem cells. J Comp Neurol. 2014 Aug 15; 522(12):2689-90.
Score: 0.027
-
Misfolded proteins in Huntington disease fetal grafts: further evidence of cell-to-cell transfer? Ann Neurol. 2014 Jul; 76(1):20-1.
Score: 0.027
-
Peripheral alpha-synuclein and Parkinson's disease. Mov Disord. 2014 Jul; 29(8):963-6.
Score: 0.027
-
The prion hypothesis of Parkinson's disease: this hot topic just got hotter. Mov Disord. 2014 Jul; 29(8):988.
Score: 0.027
-
Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
Score: 0.027
-
In memorium: Roy A.E. Bakay, MD. Mov Disord. 2013 Nov; 28(13):1809-10.
Score: 0.026
-
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
Score: 0.025
-
Trophic factor gene therapy for Parkinson's disease. Mov Disord. 2013 Jan; 28(1):96-109.
Score: 0.024
-
Cell therapy for Parkinson's disease: what next? Mov Disord. 2013 Jan; 28(1):110-5.
Score: 0.024
-
Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts. J Parkinsons Dis. 2013; 3(4):581-91.
Score: 0.024
-
Introduction: gene therapy has gone from a pipe dream to clinical reality. Neurobiol Dis. 2012 Nov; 48(2):151-2.
Score: 0.024
-
Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012 Jul; 135(Pt 7):2058-73.
Score: 0.023
-
Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012 May; 27(6):716-9.
Score: 0.023
-
Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy. Prog Brain Res. 2012; 200:221-41.
Score: 0.023
-
Gene therapy for Huntington's disease. Neurobiol Dis. 2012 Nov; 48(2):243-54.
Score: 0.023
-
GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets. 2011 Sep 01; 10(6):703-11.
Score: 0.022
-
Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012 May; 27(6):709-15.
Score: 0.022
-
Transfer of host-derived a synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011 Sep; 43(3):552-7.
Score: 0.022
-
Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med. 2011 Jan-Feb; 78(1):126-58.
Score: 0.021
-
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
Score: 0.021
-
a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
Score: 0.021
-
Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010 Jan; 1184:55-67.
Score: 0.020
-
Gene therapy for Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S161-73.
Score: 0.020
-
Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.
Score: 0.020
-
Are growth factors the answer? Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S176-80.
Score: 0.020
-
Modeling Parkinson's disease. Ann Neurol. 2009 Oct; 66(4):432-6.
Score: 0.019
-
Animal rights terrorists: what every neuroscientist should know. J Neurosci. 2009 Sep 16; 29(37):11419-20.
Score: 0.019
-
Celebrating neural repair. J Comp Neurol. 2009 Jul 01; 515(1):1-3.
Score: 0.019
-
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
Score: 0.019
-
Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another? Neuropsychopharmacology. 2009 Jan; 34(1):254.
Score: 0.018
-
Trophic factors therapy in Parkinson's disease. Prog Brain Res. 2009; 175:201-16.
Score: 0.018
-
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
Score: 0.018
-
Future of cell and gene therapies for Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S122-38.
Score: 0.018
-
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May; 14(5):504-6.
Score: 0.018
-
Introduction to the special ASNTR issue. Cell Transplant. 2008; 17(4):361-2.
Score: 0.017
-
Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol. 2008 Jan; 209(1):34-40.
Score: 0.017
-
Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord. 2007 Aug 15; 22(11):1630-3.
Score: 0.017
-
Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant. 2007; 16(3):301-12.
Score: 0.016
-
Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
Score: 0.016
-
Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
Score: 0.015
-
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S89-103.
Score: 0.015
-
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
Score: 0.015
-
Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15(3):251-65.
Score: 0.015
-
Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol. 2004 Jul 19; 475(2):211-9.
Score: 0.014
-
Primate models of Parkinson's disease. Exp Neurol. 2003 Oct; 183(2):258-62.
Score: 0.013
-
In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S120-32; discussion S132-4.
Score: 0.012
-
Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
Score: 0.012
-
Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002 Feb 04; 443(2):136-53.
Score: 0.011
-
SeqStain is an efficient method for multiplexed, spatialomic profiling of human and murine tissues. Cell Rep Methods. 2021 06 21; 1(2).
Score: 0.011
-
A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimers Dement. 2021 06; 17(6):933-945.
Score: 0.011
-
Inflammation in Experimental Models of a-Synucleinopathies. Mov Disord. 2021 01; 36(1):37-49.
Score: 0.010
-
Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
Score: 0.010
-
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. J Neurosci. 2020 04 29; 40(18):3675-3691.
Score: 0.010
-
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. 2020 03 17; 94(11):481-494.
Score: 0.010
-
Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest. 2020 02 03; 130(2):904-920.
Score: 0.010
-
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 2020 05; 139(5):855-874.
Score: 0.010
-
Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson's Disease? J Parkinsons Dis. 2020; 10(2):405-411.
Score: 0.010
-
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
Score: 0.010
-
Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
Score: 0.009
-
Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms. Acta Neuropathol. 2019 06; 137(6):981-1001.
Score: 0.009
-
Loss of One Engrailed1 Allele Enhances Induced a-Synucleinopathy. J Parkinsons Dis. 2019; 9(2):315-326.
Score: 0.009
-
Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiol Dis. 2020 02; 135:104352.
Score: 0.009
-
Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut. 2019 05; 68(5):829-843.
Score: 0.009
-
Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. Mol Neurobiol. 2018 Nov; 55(11):8728-8737.
Score: 0.009
-
Analysis of age-related changes in psychosine metabolism in the human brain. PLoS One. 2018; 13(2):e0193438.
Score: 0.009
-
Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease. Mov Disord. 2018 04; 33(4):652-654.
Score: 0.009
-
Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease. Brain. 2017 Nov 01; 140(11):2982-2992.
Score: 0.008
-
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep; 32(9):1264-1310.
Score: 0.008
-
The Search for a Peripheral Biopsy Indicator of a-Synuclein Pathology for Parkinson Disease. J Neuropathol Exp Neurol. 2017 01 01; 76(1):2-15.
Score: 0.008
-
The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. J Parkinsons Dis. 2017; 7(2):331-346.
Score: 0.008
-
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
Score: 0.008
-
Is Axonal Degeneration a Key Early Event in Parkinson's Disease? J Parkinsons Dis. 2016 10 19; 6(4):703-707.
Score: 0.008
-
Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. J Parkinsons Dis. 2016 10 19; 6(4):761-770.
Score: 0.008
-
Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease. J Biol Chem. 2016 07 15; 291(29):15267-81.
Score: 0.008
-
Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol Commun. 2016 Apr 04; 4:35.
Score: 0.008
-
Preface. Mov Disord. 2016 Feb; 31(2):151.
Score: 0.008
-
PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
Score: 0.007
-
Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum Mol Genet. 2015 Sep 15; 24(18):5285-98.
Score: 0.007
-
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
Score: 0.007
-
Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a-synucleinopathies. Neurobiol Dis. 2015 Jun; 78:162-71.
Score: 0.007
-
Neonatal immune-tolerance in mice does not prevent xenograft rejection. Exp Neurol. 2014 Apr; 254:90-8.
Score: 0.007
-
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81.
Score: 0.007
-
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011; 6(12):e28032.
Score: 0.006
-
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011 Nov 06; 480(7378):547-51.
Score: 0.006
-
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
Score: 0.005
-
?-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and ?-amyloid accumulation. Eur J Neurosci. 2010 Oct; 32(7):1223-38.
Score: 0.005
-
Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
Score: 0.005
-
Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem. 2010 Jun; 113(5):1073-91.
Score: 0.005
-
Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol. 2009 Nov; 66(5):591-6.
Score: 0.005
-
Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A. 2009 Jul 28; 106(30):12483-8.
Score: 0.005
-
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 2009 Apr; 64(4):602-12; discussion 612-3.
Score: 0.005
-
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
Score: 0.005
-
Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol. 2009 Apr; 216(2):342-56.
Score: 0.005
-
Postmortem study of deep brain stimulation of the anterior thalamus: case report. Neurosurgery. 2008 Feb; 62(2):E530-2; discussion E532.
Score: 0.004
-
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18754-9.
Score: 0.004
-
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
Score: 0.004
-
Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
Score: 0.004
-
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S469-77.
Score: 0.004
-
Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
Score: 0.004
-
Survival and early differentiation of human neural stem cells transplanted in a nonhuman primate model of stroke. J Neurosurg. 2006 Jul; 105(1):96-102.
Score: 0.004
-
Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol. 2006 Jan; 59(1):166-73.
Score: 0.004
-
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005 May; 11(5):551-5.
Score: 0.004
-
Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol. 2004 Sep; 33(5):517-33.
Score: 0.003
-
The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003 Sep; 4(9):727-38.
Score: 0.003
-
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
Score: 0.003
-
Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system. J Comp Neurol. 2003 Aug 25; 463(3):341-57.
Score: 0.003